clinical trial · NCT03809325
A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
Janssen-Cilag International NV·—·completed·n = 225
SchizophreniaPaliperidone Palmitate 3-Month Formulation (PP3M)
brief summary
The purpose of this study is to explore the experience with paliperidone palmitate 3-month formulation (PP3M) treatment of participants and their corresponding physicians, nurses and carers, to understand the impact of less frequent injections from their perspective.
started
Nov 21, 2018
primary completion
Jul 12, 2019
completion
Jul 12, 2019
last updated
Apr 27, 2025
official title
Cross-sectional Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol